Antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Root
Report Keywords – Antibody Drug, Conjugates, Roots Analysis, Biotech, Analysis
Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community
Roots Analysis is pleased to announce the publication of its recent study, titled, “ Antibody Drug Conjugates Market (5th Edition), 2019-2030.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of ADCs.
Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.
An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
A list of key opinion leaders (KOLs) within this domain.
An insightful competitiveness analysis of biological targets.
An analysis of the partnerships that have been established in the recent past.
An analysis of the investments made.
A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April).
An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch.
An analysis of the key promotional strategies that have been adopted by the developers of marketed products.